Last updated: February 4, 2026
What is the scope of the litigation?
Mallinckrodt LLC filed patent infringement claims against Lupin Ltd and its U.S. subsidiary, Lupin Pharmaceuticals Inc., on February 7, 2012, in the District of Delaware. The case targets Lupin’s alleged infringement of U.S. Patent No. 8,077,594 ("'594 patent") related to a drug product used for treating certain medical conditions.
The core issue involves Lupin’s manufacture and sale of a generic version of Mallinckrodt's marketed opioid pain medication, which Mallinckrodt argues infringes upon its patent rights.
What patents are involved?
The patent at issue is U.S. Patent No. 8,077,594, issued on December 13, 2011, titled "Extended Release Formulation." It claims a controlled release formulation of oxymorphone with specific release characteristics.
Key features include:
- Matrix-based controlled release with a specific polymer composition.
- Release profile parameters tested in vitro and in vivo.
- Intended to provide extended analgesic effects with consistent blood plasma levels.
The patent term extends to at least 2028, providing Mallinckrodt with potential exclusivity until then.
What are the main accusations?
Mallinckrodt alleges that Lupin’s generic oxymorphone products infringe the '594 patent. Central allegations include:
- Direct infringement via manufacturing, marketing, and sale.
- Indirect infringement through inducement and contributions for infringement.
Mallinckrodt argues that Lupin’s formulations use similar controlled-release mechanisms, infringing the patent’s claims. Lupin contends that its products do not infringe and raises invalidity defenses.
What defenses does Lupin raise?
Lupin’s primary defenses include:
- Non-infringement due to differences in formulation or release profile.
- Patent invalidity based on obviousness, lack of novelty, or anticipation.
- Inequitable conduct during patent prosecution.
- Non-infringement as a matter of law based on claim construction.
Lupin also questions the patent’s enforceability, citing prior art references and its own development activities.
What has been the procedural history?
- 2012: Complaint filed, patent infringement asserted.
- 2014: Markman hearing and claim construction proceedings initiated.
- 2015: Summary judgment motions and pretrial conferences held.
- 2016: Jury trial scheduled but delayed due to settlement negotiations.
- 2017: Case stayed pending inter partes review (IPR) petitions filed by Lupin.
The proceedings have involved multiple motions on claim scope, validity, and related issues, with the case remaining active as of the most recent filings.
What is the current status?
- The IPR petitions are pending before the Patent Trial and Appeal Board (PTAB).
- The district court has stayed all proceedings pending IPR outcomes, as per recent orders.
- The case remains unresolved, with potential outcomes including infringement finding, invalidity ruling, or settlement.
What are the broader implications?
This case exemplifies patent challenges in the pharmaceutical industry, especially regarding formulations and extended-release technologies. The outcome could influence:
- The patent’s enforceability and scope.
- The timing of generic entry into the U.S. market for oxymorphone.
- Strategies for patent drafting and litigation in controlled-release drugs.
Key differences from other cases
Compared to typical Hatch-Waxman litigations:
- The patent pertains to formulation-specific features rather than active ingredients.
- The case was delayed by inter partes review proceedings, a strategic tool for defendants.
- It features a detailed claim construction process addressing complex formulation language.
Key Takeaways
- The case underscores the importance of patent claim language and its interpretation in pharmaceutical patent infringement.
- Patent validity arguments, especially prior art references and obviousness, play a critical role in litigation outcomes.
- The stay pending IPR highlights procedural tactics in patent disputes, influencing patent rights and market competition.
- The case illustrates the intersection of patent law and regulatory approval processes, particularly with FDA considerations.
- As of now, the case’s resolution remains uncertain, and subsequent decisions could shape industry practices.
FAQs
1. What is the significance of the inter partes review in this case?
IPR proceedings allow Lupin to challenge the validity of the '594 patent, potentially leading to invalidation. A decision in IPR could significantly impact the infringement case’s outcome and market entry strategies.
2. Has the court found any infringement or invalidity?
No final ruling has been issued. The proceedings are ongoing, with key issues deferred pending IPR outcomes.
3. How does this case compare to other pharma patent disputes?
It involves formulation-specific patents, raising complex issues about patent scope and validity. The case also highlights strategic use of IPR proceedings.
4. What are the potential consequences for Lupin if the patent is upheld?
Lupin could face injunctions preventing product sales, damages, and increased litigation costs. They may need to design around the patent or wait until patent expiry.
5. What role does claim construction play in this litigation?
Claim construction defines the scope of patent rights, affecting infringement and invalidity analyses. The court’s interpretation influences both parties’ strategies and potential settlement.
Sources
[1] U.S. Patent No. 8,077,594.
[2] Court docket for Mallinckrodt LLC v. Lupin Ltd, 1:12-cv-01087, District of Delaware.
[3] Federal Court records and public filings.
